The above findings suggest that dysregulation of ATG13 expression is involved in gastric cancer progression and may serve as a candidate survival biomarker for this malignancy, which warrant further validation by further in vitro/in vivo models and clinical studies to strengthen the mechanistic evidence and translational potential in our future work.
You et al. (Fri,) studied this question.